Clinical Trials · NCT05931380
A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 238
- Start date
- Jul 2023
- Locations
- 16 sites, Japan
- Primary endpoint
- Percent Change From Baseline in Body Weight at Week 72